Sullivan Christopher Ryan Insider Trading -- Recent SEC Form 4 Transactions

Sullivan Christopher Ryan (CIK 1810417) reported 20 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-06-12). Recent activity: Sell AVTX (138 shares), Buy AVTX (18,606 shares), Sell AVTX (18,606 shares), Buy AVTX (47,000 shares), Sell AVTX (13,834 shares). Source: SEC Form 4.

DateCompanyRoleTypeSharesValue
2026-06-12Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerSell138$1,808
2026-05-11Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerBuy18,606$183,827
2026-05-11Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerSell18,606$448,818
2026-05-07Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerBuy47,000$377,880
2026-05-07Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerSell13,834$256,655
2026-05-07Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerSell12,347$238,093
2026-05-07Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerSell2,700$56,052
2026-05-07Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerSell9,219$197,008
2026-05-07Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerSell8,900$200,913
2026-05-01Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerSell8,458$110,736
2026-05-01Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerSell8,457$111,853
2026-04-03Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerSell500$7,929
2026-04-03Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerSell7,479$125,841
2026-04-03Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerSell6,200$105,553
2026-04-03Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerSell1,780$31,270
2026-03-31Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerBuy24,200$0
2026-03-31Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerSell8,241$114,467
2025-12-12Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerSell155$636
2025-04-01Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerBuy24,200$0
2025-04-01Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerSell7,285$61,631

Source: SEC Form 4 filings · as of 2026-06-12